Selumetinib Hydrogen Sulfate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Selumetinib Hydrogen Sulfate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
137
Registered trials
139
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Selumetinib Hydrogen Sulfate can convert its Small molecule drug profile and MEK1 x MEK2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Selumetinib Hydrogen Sulfate (query alias: selumetinib) |
|---|---|
| Modality / target | Small molecule drug; MEK1 x MEK2; MEK1 inhibitors, MEK2 inhibitors |
| Highest global status | Approved |
| Originator | Array BioPharma, Inc. |
| Active developers | AstraZeneca PLC, National Cancer Institute, The University of Texas MD Anderson Cancer Center |
The MCP disease footprint includes NF1 mutant Plexiform Neurofibroma, Neurofibromatoses, Neurofibromatosis 1. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06763315 | Phase 2 | Not yet recruiting | 50 | The change in tumor volume of plexiform neurofibromas |
| NCT06620354 | Phase 2 | Not yet recruiting | 33 | Objective response rate (ORR) |
| NCT06735820 | Phase 1/2 | Not yet recruiting | 45 | The number of treated patients with adverse events as determined by the common criteria for adverse version 5 (CTCAEv5). |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Final analysis of KOMET (NCT04924608), a phase 3 study of selumetinib in adults with NF1-PN.
Phase 3; n=145; evaluation: Positive. Reported fields: ORR = 23.9 % ( 14.6 - 35.5)
SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Phase 2; n=21; evaluation: not stated. Reported fields: Clinical Benefit Rate of Selumetinib in Combination With Sirolimus in Patients With Unresectable or Metastatic NF1 Associated or Sporadic MPNST. = 0.095 Proportion (95% Confidence Interval, 0.0167 - 0.32); Clinical Benefit Rate of Selumetinib in Combination With Sirolimus in Patients With Unresectable or Metastatic NF1 Associated or Sporadic MPNST.: proportion of participants = 0.095(95% CI, 0.0167 - 0.32); Clinical Benefit Rate of Selumetinib in Combination With Sirolimus in Patients With Unresectable or Metastatic NF1 Associated or Sporadic MPNST.: proportion of participants = 0.095(95% CI, 0.0167 - 0.32)
A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumetinib or Capivasertib, or Ceralasertib Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer
Phase 2; n=24; evaluation: not stated. Reported fields: -; -; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Selumetinib Hydrogen Sulfate addresses NF1 mutant Plexiform Neurofibroma, Neurofibromatoses, Neurofibromatosis 1. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-09-27 | Alexion collaborates with Nagoya University to conduct a phase II clinical trial to evaluate the efficacy of Koselugo in treating neurofibromatosis type 1. | Phase 2 | Financial terms not disclosed |
| 2020-03-18 | NCI to collaborate with AstraZeneca in a Cooperative Research and Development Agreement (CRADA) to carry out a phase II clinical trial of selumetinib for the treatment of neurofibromatosis type 1. | Phase 2 | Financial terms not disclosed |
| 2017-07-27 | AstraZeneca and Merck Establish Strategic Oncology Collaboration | Phase 3 | US$1,600.0M upfront; US$6,150.0M milestones; US$8,500.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
